Thus, we suggest that individuals with LBD, particularly females with one or more APOE ε4 alleles, could be considered candidates for treatment with amyloidocentric drugs, should they show efficacy in slowing cognitive decline in patients with AD. The gene discussed is APOE; the disease is Alzheimer disease.